WZWenhui Zhang

Wenhui Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenhui Zhang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Xue

    State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

    4 shared publications
  • Lei Zhang

    State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin Key Laboratory of Gene Therapy for Blood Diseases CAMS Key Laboratory of Gene Therapy for Blood Diseases Tianjin China

    4 shared publications
  • Lingling Chen

    State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin Key Laboratory of Gene Therapy for Blood Diseases CAMS Key Laboratory of Gene Therapy for Blood Diseases Tianjin China

    4 shared publications
  • Man-Chiu Poon

    Cumming School of Medicine, University of Calgary, Calgary, Canada

    3 shared publications
  • Renchi Yang

    State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin Key Laboratory of Gene Therapy for Blood Diseases CAMS Key Laboratory of Gene Therapy for Blood Diseases Tianjin China

    3 shared publications
  • Wei Liu

    State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin Key Laboratory of Gene Therapy for Blood Diseases CAMS Key Laboratory of Gene Therapy for Blood Diseases Tianjin China

    3 shared publications

Latest Publications

  • Women and girls with haemophilia: A retrospective cohort study in China

    by Wenhui Zhang, Kuixing Li, Man‐Chiu Poon, Xinsheng Zhang, Jingsheng Wu, Xielan Zhao, Min Zhou, Xuefeng Wang, Mei Zhang, Weiqun Xu, et al.

    Introduction: Women and girls with haemophilia (WGH) may have spontaneous/traumatic bleeding similar to that in males with haemophilia, and in addition excessive bleeding during menstruation and delivery.Aim: To characterize WGH in China and provide guidance for better management.Methods: We retrospectively analysed the characteristics of WGH registered in the Haemophilia Treatment Center Collaborative Network of China (HTCCNC) Registry, including demographics, diagnosis and treatment, bleeding characteristics, obstetrical and gynaecological experiences, and surgical history.Results: A total of 61 females had confirmed haemophilia. Diagnosis and treatment were typically delayed, longer in mild haemophilia than in severe and moderate. The most frequently reported bleeding manifestations were haemarthrosis in severe and moderate patients, and cutaneous bleeding in mild patients. Among 45 postmenarcheal WGH, 21 (46.7%) had history of heavy menstrual bleeding, but only three received treatments. Prenatal diagnosis and management of perinatal haemorrhage were inadequate. Of 34 deliveries in 30 women, nine deliveries were complicated by postpartum haemorrhage, and 22 offspring carried mutations causing haemophilia. Forty‐four surgical procedures were performed in 29 patients. Those procedures receiving preoperative coagulation factors coverage were significantly less likely to have excessive bleeding than those who did not (P = .003).Conclusion: This is the first and largest study describing WGH in China. There are currently deficiencies in the identification, diagnosis, and management of these patients. Improving health insurance policies, establishing haemophilia centres, and multidisciplinary teams for bleeding and perinatal or perioperative management will help reduce morbidity and mortality.


  • Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China

    by Xueqing Dou, Wenhui Zhang, Man‐Chiu Poon, Xinsheng Zhang, Runhui Wu, Xiaoqin Feng, Linhua Yang, Peng Cheng, Shu Chen, Ying Wang, et al.

    Introduction: The development of inhibitors against factor FIX (FIX) is the most serious complication of FIX replacement therapy in haemophilia B (HB) patients. Currently, only few cohorts of HB inhibitor patients have been reported worldwide.Aim: This Chinese nationwide study of HB inhibitor patients explored their risk factors for FIX inhibitor development and experience on their management.Methods: We retrospectively analysed patient characteristics, F9 genotypes, treatment strategies and outcomes of HB inhibitor patients registered to the Chinese National Registry and Patient Organization Registry.Results: Forty‐four unique HB inhibitor patients were identified in 4485 unique HB patients registered by year 2021 to the two Registries. Inhibitor diagnosis were usually delayed and the low prevalence (.98%) may suggest some inhibitor patients were not identified. Their median age at inhibitor diagnosis was 7.5 (IQR, 3.0–14.8) years. Most patients (95.5%) had high‐titre inhibitors. Allergic/Anaphylactic reactions occurred in 59.1% patients. Large deletions and nonsense mutations were the most common F9 mutation types in our FIX inhibitor patients. Patients with large F9 gene deletions were more likely to develop inhibitors (p = .0002), while those with missense mutations had a low risk (p < .0001). Thirteen (29.5%) patients received immune tolerance induction (ITI) therapy using low‐dose prothrombin complex concentrate regimens. Twelve completed ITI with three (25.0%) achieving success. Nephrotic syndrome developed in two (16.7%) patients during ITI.Conclusion: This study reports the largest Chinese cohort of HB inhibitor patients. Large deletions were most significantly associated with inhibitor development. Low‐dose ITI might be feasible for FIX inhibitor eradication.


  • Health‐related quality of life among adults with haemophilia in China: A comparison with age‐matched general population

    by Wenhui Zhang, Shitong Xie, Feng Xue, Wei Liu, Lingling Chen, Lei Zhang, Jing Wu, Renchi Yang

    Introduction: Evaluating health‐related quality of life (HRQoL) is vital for informing the improvement of the overall health of people with haemophilia (PwH). While there is lacking such data in China and comparisons with the general population.Aim: To evaluate the HRQoL and its associated factors among adults with haemophilia, and compare it with a sample of the general population in China.Methods: PwH were recruited in this study using telephone‐based interviews. Demographic and clinical characteristics were first collected. HRQoL was then evaluated using the self‐reported Short Form 6‐dimensions version 2 (SF‐6Dv2) instrument. An age and gender‐matched sample of the general population in China was also included as the comparator group. Linear regression was used to assess the association between the SF‐6Dv2 utility value and the demographic and clinical variables of the patients.Results: This study included 206 PwH (mean [SD] age: 41.36 [14.48] years) and 206 respondents from the general population. PwH reported worse levels in physical functioning, role limitation, social functioning, and mental health dimensions on SF‐6Dv2 than the general respondents. The mean (SD) utility of patients was .650 (.251), which was significantly lower than the general respondents (.786 [.183],P < .001). Being a student, having a higher monthly income, absence of comorbidities, having no target joints and requiring no treatment are independent predictors of a higher HRQoL for PwH.Conclusion: This study provides the first practical evidence of a significantly lower level of HRQoL in PwH than in the general population in China.


  • Demographics, clinical profile and treatment landscape of patients with haemophilia B in China

    by Wenhui Zhang, Xuewen Song, Xueqing Dou, Man‐Chiu Poon, Wei Liu, Lingling Chen, Lei Zhang, Feng Xue, Renchi Yang